Quercis Pharma AG
Clinical Stage Biotech – disrupting the $50bn cancer immunotherapy PD-1/PD-L1 market. Lead asset code-named Kinisoquin™ in Phase 3 Trial under FDA SPA. Targets PD-L1, VEGF, PDI TF, TMEM176 in Cancer, Thrombosis and Neurology. Potentially Best-in-Class Oral Therapeutic in the PD-1/PDL1 market with safety and efficacy advantages over PD-1 VEGF bispecific antibodies. Scientific Advisory Board consists of Global A-Team in Hematology Oncology and Neurology.
Date, time and room information
May 6, 16:00 - 16:15, room Montreal
Category
Clinical stage development company
Title of the presentation
Quercis Pharma - Exploring Newly Discovered Immune Pathways in Cancer
Speaker information
| Name | Position | Institution |
|---|---|---|
| Thomas Lines | CEO |
